Is this a "Killer acquisition"?, page-3

Chronic respiratory management for Asthma (children and adult) and COPD (adult) is also a massive market for big pharma which is why Jansen (subsidiary of J&J) is doing clinical trial using ResAppDx for AVS. It will allow them to offer ResAppDx exclusive to their patients when using their drug which will mean these big pharma will be signing a lot more Asthma and COPD patients for their entire life time hence I see Pfizer increasing their bid to at least 30c......